Crossmark

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience

Crossref DOI link: https://doi.org/10.1007/s11060-018-2847-z

Published Online: 2018-04-10

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Coleman, Niamh https://orcid.org/0000-0002-5803-9528
Michalarea, Vasiliki

Alken, Scheryll

Rihawi, Karim

Lopez, Raquel Perez

Tunariu, Nina

Petruckevitch, Ann

Molife, L. R.

Banerji, Udai

De Bono, Johann S.

Welsh, Liam

Saran, Frank

Lopez, Juanita
License Information

Text and Data Mining valid from 2018-04-10
More Information

Article History

Received: 9 October 2017

Accepted: 25 March 2018

First Online: 10 April 2018

Compliance with ethical standards

:

: There are no conflict of interest for all authors.